



2025 ANNUAL REPORT

HL7[®]

 Europe

[HL7europe.org](https://hl7europe.org)

Table of Contents

Table of Contents.....	1
HL7 Europe	4
What we do	5
Secretary General, Highlights 2025	6
HL7 Europe Board Chair, Strategic Review 2025.....	8
Key Achievements.....	9
EU Funded Projects Update	12
Gravitate Health - Empowering and Equipping Europeans with health information for Active Personal Health Management Adherence to Treatment.....	13
PanCareSurPass: PanCare studies of the scale-up and implementation of the digital Survivorship Passport to improve people-centred care for childhood cancer survivors. 14	
xShare: Expanding the European EHRxF to share and effectively use health data within the EHDS	15
NextGen: Personalised Medicine, Prediction, Prevention, Diagnosis, Treatment of Cardiovascular Disease	16
Protect-Child: Data integration for improved outcomes in child transplants	17
IDEA4RC: Intelligent Ecosystem to improve the governance, the sharing and the re-use of health Data for Rare Cancers	18
FLUTE: Pioneering secure healthcare AI across borders	19
One Aqua Health: Protecting Urban Aquatic Ecosystems to Promote One Health	20
READI: Research in Europe and Diversity Inclusion.....	21
CAREPATH: Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health	22
myHealth@myHands: Person-Centred Health Management through access to their health data using the EUDI Wallet Services	23
i2X: Intelligent Implementations of the European EHR Exchange Format.....	24
Key Initiatives	25
HL7 Europe Cancer Initiative	25
Phoenix HL7 Europe FHIR Initiative Phases.....	26
The Phoenix 3 Year Plan – Major Objectives.....	27
Common Cancer Data Model Project	27
Collaboration and Cross Project Synergy	27
HL7 Europe Facility.....	28

Hospitals on FHIR®	30
Membership and Country Ambassadors	30
HoF Ambassadors	30
HoF Events 2025	31
Session Highlights.....	32
Hospitals on FHIR® European Network.....	35
Hospitals on FHIR® Maturity Model	35
Hospitals on FHIR® Governance	36
HL7 Europe Working Group Meetings 2025	37
Participation in HL7®FHIR®Accelerators	39
HL7®FHIR®Accelerator Vulcan: Connecting Clinical Research to Health Care	39
Advising, Collaboration, and Liaison Activities	40
Liaison CEN/CENELEC Technical Committee 251	40
European Federation for Medical Informatics (EFMI)	40
eHealth Stakeholders Group (eHSG).....	42
Advisor to NFDI4Health.....	42
Summary of 2025	42
Communications and Outreach 2025.....	43
Profile view highlights	43
BlueSky	44
Email Marketing.....	45
Website visit highlights	45
Website Improvements	46
HL7 Europe – European Projects’ webpage.....	46
HL7 Europe - Event Highlights.....	47
HL7 Europe – Scientific Publications section	47
HL7 Europe Governance.....	49
Organizational Structure	49
HL7 Europe Board of Directors 2025 - 2026:	49
European Technical Coordination Team.....	50
Communications Task Force	50
European Standardization Projects under the EU Realm.....	51
European Advisory Council	52

Affiliate Map	52
Treasurer Report	53
Financial Report	54
HL7 Europe Annual Results 2025	54
Annual Accounts Statement 2025.....	55
Statement of Certified Accountant 2025	59
HL7 Europe's Future Outlook	63
Acknowledgements	64
Key Highlights Summary.....	65
Appendix.....	66
Scientific Articles published in 2025	66

HL7 Europe

Health Level Seven® (HL7®) International, a not-for-profit, ANSI-accredited, Standards Development Organization (SDO), dedicated to developing a comprehensive framework and related standards for the exchange, integration, sharing, and retrieval of electronic health information. Our standards support the efficient management, delivery, exchange and evaluation of healthcare data and services. (<https://www.hl7.org>)

HL7 Europe Foundation is a private foundation, established in 2010 by HL7® International, as regional European office of Health Level Seven® (HL7®) International in Brussels, Belgium, to address European standardization requirements in digital health. The mission of HL7 is to provide standards that empower global health data interoperability to realize the vision of a world in which everyone can securely access and use the right health data when and where they need it. Working in close cooperation with 23 HL7® Affiliates in the European region, HL7 Europe is responsible for the EU Realm and supports the creation of health information technology standards that are widely used enabling interoperability in healthcare. HL7® Europe also encourages the consistent adoption of HL7® standards in European health systems and provides education services, promotes tools and facilitates testing and certification. HL7 Clinical Document Architecture (CDA) is used by myHealth@EU to record patient summaries and ePrescriptions and slowly we witness the uptake of HL7 Fast Healthcare Interoperability Resources (HL7® FHIR®), in specifications for laboratory results, hospital discharge reports and imaging reports. HL7 Europe is a member of the eHealth Stakeholder Group of the European Commission. HL7 Europe is also active in the development of EEHRxF specifications for the European Health Data Space developing and supporting work with HL7® FHIR® IGs. (<https://fhir.org>)

The incumbent HL7 Europe Board of Directors (BoD), took office in 2025 for two years, and was formed to include Jan-Eric Slot as Board Chair, Roman Radomski MBA, as treasurer and Joao Almeida, PhD as Secretary. The BoD includes a total of thirteen Directors, of which five members are from HL7 International Board (US) and eight are Europeans. This ensures that the BoD has a strong European perspective, limits control of HL7 International and cultivates collaboration with HL7 Affiliates in Europe, HL7 Europe with the active engagement of the HL7 Europe Technical Coordination Team (TNT) of European HL7 Affiliate Technical leads, is responsible for the HL7 EU Realm and contributes to the development of global, connected digital health standards with European Input.

HL7 Europe supports the vision of HL7 and is committed to advancing interoperability in healthcare by creating and fostering the adoption of widely used health IT standards in the European region. Through the dedication of our community, volunteers, and associates, we strive to achieve our mission of advancing towards a world where individuals can securely access and utilize their health data at any time and in any place.

What we do

HL7 Europe is responsible for the HL7 EU Realm and participates in European and Global collaborations that drive widespread use of HL7 frameworks, protocols, standards and specifications within and across healthcare organizations to enable data sharing and interoperability with special focus on the European Union and the European region by WHO. HL7 Europe is an active participant in European Union funded Research and Technological Innovation projects, including the Horizon Program, and over the years has been coordinator of 4 projects (Trillium Bridge, Trillium II, eStandards and xShare), while it has been active participants in more than 30. All these projects highlight cooperation among standards organizations across Europe and globally. The currently active xShare (2023-2026) aims to empower individuals to share their health data at the click of a button in the EHDS using the EEHRxF that is based on HL7® FHIR®.

HL7 Europe produces HL7 FHIR Implementation Guides (IGs) for the priority data categories of the EHDS. It collaborates with other European umbrella organizations active in digital health. It has a liaison A relation with CEN/CENELEC, a collaboration agreement with IHE Europe, while it collaborates closely with EFMI and HIMSS. It has also established and hosts the Hospitals on FHIR community and the PHOENIX initiative for Cancer, to advance adoption of FHIR in health care facilities, and promote alignment, coordination, and interoperability among Cancer stakeholders. HL7 Europe features and maintains key results of EU projects in the HL7 Europe facility sustaining the results of EU projects.

HL7 Europe also delivers educational resources and webinars supporting the development of essential tools and facilitating the rigorous testing and certification of information systems to optimize healthcare delivery and reduce costs. These HL7 activities and initiatives are made possible through participation in EU funded research programs.

Secretary General, Highlights 2025



HL7 Europe continued to grow in 2025 under the strong leadership of the HL7 Europe Board of Directors. Key areas of focus include actively monitoring developments in the European digital health landscape and ensuring that the focus areas and activities of HL7 Europe align with cross-European digital health initiatives and activities to promote interoperability and the advancement of digital health in Europe for citizens. HL7 Europe has been active in EHDS with the xShare project that presented innovative uses of the xShare “yellow” button and with strong pan European HL7 Affiliate support in the TNT, the development of HL7 FHIR IGs for all six priority data categories under EHDS. In order to provide further support to the EHDS, HL7 Europe signed an agreement with the xtEHR joint actions, continued its collaboration with IHE Europe, CEN TC251, participated as an associate partner in the XiA project – to advance education in the EHDS, collaborates with the EMA to align SPOR to the EHDS.

HL7 Europe is also active in Cancer related projects i.e. Flute, PCSP, and IDEA4RC contributing into a logical model for Cancer in Europe. There are also projects related to federated learning and Genomics, in cardiology and children transplantation i.e. NextGen and Protect-Child. Meanwhile we continue to work with Vulcan Accelerator electronic Product Information (ePI) program under the Gravitare-Health IMI project, where HL7 Europe are the interoperability lead and program owner. Finally, we contribute to the green deal and climate action with our participation in the OneAquaHealth project, a project that looks to connect the health of the environment, animals and plants to the health of people in a OneHealth context.

The Technical Coordination Team (TNT) for Europe, chaired by Giorgio Cangilioli, the Technical Lead of HL7 Europe continues to oversee and coordinate the development of HL7 standards in Europe. More than a hundred people follow the conference calls of HL7 Europe Standardization projects. HL7 Europe continues to advance and promote the following key programs and initiatives. The European Strategic Advisory Board, comprising affiliates in European region, continues to advise HL7 on matters of their jurisdiction and collaborates on requirements for HL7 standards.

In 2025, under the leadership of Kai Heitmann, had the 2nd and 3rd HL7 Europe working group meetings, Lisbon, February 10-14, 2025, and Cologne December 1-5, 2025, each attracting 100 to 150 people around Europe. The European Affiliate Council met on both occasions. In Cologne it was a joint meeting with the board of HL7 Europe.

The **Hospitals on FHIR®** (HoF) initiative, started in 2023, continues to grow with more than 100 members across Europe and will play a crucial role in shaping the future of healthcare in Europe. Over the last two years we have seen a significant increase in interest in Hospitals on FHIR User Days and webinars where the primary focus is on sharing implementation experiences and networking to generate implementation solutions. In 2025, the Hospitals

on FHIR user days partnered with XiA and the German Interoperability Forum in Berlin on October 9-10 and brought together members across Europe as well as the interest of companies supporting Hospitals with FHIR infrastructure.

In the area of funded projects, the surge in funded projects won in 2023 continues to support the organization and the increase in team members to position HL7 Europe for future growth. The impact of this funded expansion will accelerate the delivery of fit-for-purpose, HL7 specifications and HL7 FHIR IGs, making them freely available and empowering European healthcare organizations and patients to exchange health information. The HL7 Europe team has grown quite significantly with now more than 25 people working parttime in exciting innovative projects.

Current ongoing projects include the **IDEA4RC** project focused on solid tumour cancers started in September 2022, along with **OneAquaHealth**, linking urban stream health to human well-being. After 4 years of intense work, the **PanCareSurPass** project implementing HL7 FHIR connections to the childhood cancer survivorship passport in 6 countries, concluded in August 2025. The **Flute** project for synthetic data in pancreatic cancer is ongoing and progress on the European EHR Exchange format is strong in **xShare**, which aims to deliver the “yellow” button for, with HL7 Europe as Technical Coordinator, are among the most high-profile projects. At the same time, HL7 Europe collaborates closely with the **HL7® FHIR® Vulcan Accelerator** to connect healthcare data and clinical trial data effectively, co-leading the ePI track as part of the Gravitare Health project which is funded by the EU IHI program. The **READi** project also started in January tackling the problem of diversity and underrepresented populations in clinical trials and connects with the HL7 FHIR Vulcan Accelerator Utilizing the Digital Protocol (UDP) project in the definition of protocol inclusion/exclusion criteria.

Indeed it was a quite intense year, with several presentations to advance xShare, workshops and panels in venues around the world January Tedhas2 Stakeholder Forum in Warsaw, March with DIA Europe in Basel, May with MIE 2025 in Glasgow, HIMSS Europe in Paris, CDISC Interchange in Geneva, August with MedInfo 2025 in Taipei, October with Vulcan & TEDHAS2 in Copenhagen & Hospitals on FHIR in Berlin, November with AMIA in Atlanta, ending with December with the 10th year anniversary of I~HD in Ghent, with the WGM of HL7 Europe in Cologne, closing with Health & Tech in Marseille.

Catherine Chronaki

Secretary General, HL7 Europe

HL7 Europe Board Chair, Strategic Review 2025



Before we dive into our strategic review, I must start on a heavy note. At the end of 2025, we lost a giant of our community, Bert Kabbes. His passing is a profound blow, not only to HL7 Netherlands but to the entire HL7 Europe family. Bert was more than a colleague; he was a bridge-builder and a mentor to many in this room. To honor his immense legacy, the Bert Kabbes Memorial Seminar took place online on March 16th 2026, a celebration of his contributions to ensure his vision for interoperability continues to guide us.

2025 was a Year of Momentum. Looking back at 2025, it was a year where HL7 Europe truly found its stride:

- WGMs in Lisbon and Cologne: We successfully hosted two landmark Working Group Meetings. Lisbon gave us the energy, and Cologne provided the technical depth, showing a record-breaking engagement from our community.
- The Phoenix Cancer Initiative: We didn't just talk about standards; we applied them to the most pressing clinical challenges. Through the Phoenix initiative, we are proving that FHIR is the primary vehicle for the European Beating Cancer Plan.
- ESHIA & IHE: We have solidified our seat at the leadership table. As a founding member of ESHIA, we are shaping policy. Simultaneously, our joint approach with IHE Europe has moved from a "nice-to-have" to a strategic reality, providing the market with the unified guidance it has been asking for.

The Strategic Pivot. The most significant shift of 2025 has been the evolution of our "Reason for Being." Historically, HL7 Europe's "traditional" purpose was often seen through the lens of individual EU research projects. While those remain important, we are pivoting. Our focus is now squarely on European Health Data Space (EHDS) initiatives and Affiliate support:

- Becoming the technical engine behind the EHDS with meaningful initiatives
- Shifting our resources to empower our National Affiliates. As the EHDS becomes law, our Affiliates are the ones who must implement it on the ground. Our success is now measured by their readiness.

Global Presence and the road to Rotterdam. Finally, we have ensured that Europe's voice is heard globally. Our strong presence at the Madrid WGM was not just a visit; it was a mission. We successfully integrated European requirements—particularly around Lab and Hospital Discharge reports—into the global roadmap.

This sets the stage perfectly for our upcoming work in Rotterdam. There, the EHDS will not just be a topic of discussion; it will be the primary interest and focus of our technical tracks. In 2025, we transitioned from a participant to an architect. In 2026, we must remain the builders. Thank you for your hard work and for keeping Bert's spirit alive in the progress we make today.

Jan-Eric SLOT, MB MSc MBA CHCIO CDH-E

Chair HL7 Netherlands & HL7 Europe

Key Achievements

Outreach and Collaboration



Hospitals on FHIR® (HoF): This community of practice is vital to the adoption of the European EHR Exchange Format and the engagement of European Healthcare Facilities with the EHDS, aims to promote the adoption of HL7® FHIR® within the European healthcare landscape, focusing on hospitals, and the IT companies supporting them. HL7® FHIR® designed to be flexible and adaptable, making it easier to share data between different systems and organizations to help improve interoperability, healthcare and to drive innovation.

Current HoF Co-Chairs are Maria Bastos Salazar (CIO, ULSS Antonio Porto, Portugal) and Stefano Dalmiani (CDO, FMTH, Italy). The Terms of Reference were recently updated to provide guidance for members of HoF. (<https://www.hospitalsonfhir.eu>).

Key achievements: At the close of 2025, our community consisted of 135 active members, and 12 dedicated Hospitals on FHIR Ambassadors, representing 8 countries: France Belgium, Italy, Portugal, Spain, Germany, Norway, and Lithuania. The HoF community continues to grow, with membership efforts ongoing in 2025.

HL7 Facility: The HL7 Europe Facility provides a comprehensive suite of tools and services to assist both current and potential users in understanding, testing, validating, and implementing HL7 EU standards and EU project specifications. The facility includes a set of sandboxes equipped with HL7 FHIR APIs, which enable users to experiment with storing, searching, and retrieving HL7 FHIR examples, as well as validating them. These sandboxes are often enhanced with dedicated plugins for displaying stored examples and managing associated questionnaires.

Key Achievements: In 2025, the Facility continued to evolve significantly, expanding both its tooling and overall capabilities. Enhancements include plans for an HL7 FHIR Terminology Server to support terminology resources relevant to HL7 EU standards and European projects. To date, more than 36,644 visits have accessed the Facility. The HL7 Europe Sandbox provides access to HL7 Europe tools and sandboxes.



HL7® FHIR® Accelerator Vulcan: the accelerator for connecting clinical research to health care. Under the umbrella of the IHI Gravitare-Health public-private partnership project and in close collaboration with regulatory agencies European Medicines Agency (EMA), and regulatory agencies outside Europe including the United States Food and Drug Administration (FDA) and the Japanese Pharmaceutical and Devices Agency (PMDA) and the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA).

HL7 Europe co-leads the Vulcan electronic Product Information (ePI) / eLabeling project, which was formed to develop a global Implementation Guide (IG) for ePI in collaboration with the EU funded Gravitare-Health Project (www.gravitarehealth.eu) and other stakeholders (<http://www.hl7.org/vulcan/>).

Key achievements: HL7 Europe continues to participate and support the Vulcan accelerator in many ways: Collaborated with the Gravitare-Health project in the development and alignment of the HL7® FHIR® ePI IG with the EMA FHIR IG as well as those of member states. Partnered with the Global IDMP Working Group (GIDWG) (www.gidwg.org) network of regulators to promote IDMP. Supported alignment between healthcare and clinical research through HL7 FHIR–based interoperability. Contributed to Vulcan initiatives including Utilizing the Digital Protocol (UDP) and Schedule of Activities (SoA). Helped align HL7 FHIR, CDISC, OMOP, and EHDS frameworks across European projects. Supported projects such as READI and Protect-Child in implementing reusable FHIR-based research standards. Facilitated collaboration between healthcare, research, regulatory, and standards communities. Promoted adoption of computable protocols, reusable research artefacts, and interoperable clinical research workflows. Advanced education, dissemination, and implementation of Vulcan-aligned FHIR solutions across Europe.



Several HL7® FHIR® Implementation Guides were delivered or maintained supported by EU projects: the Gatekeeper HL7 FHIR IG, PCSP HL7® FHIR® IG, IDEA4RC HL7® FHIR®.

Additionally, the “[EFMI FAIR – FAIR data in Health Research Performing Organizations \(HRPOs\)](#)” working group was established to further maintain the HL7 FAIRness for HL7® FHIR® IG, that was developed in the project FAIR4HEALTH.

Key among them was the work on the HL7® FHIR® Laboratory IG, one of the priority data categories in the EHDS. Between March 2024 and May 2025 HL7 Europe produced seven webinars to promote awareness and adoption of the Lab IG. After an initial announcement and introduction, the following webinars featured adoption strategies in six EU countries (BE, NL, PT, DE, SE, ES) where country experts reported from their respective national contexts, followed by expert panels and open Q&As. Registration and attendance fluctuated between 50 and 200, with a clear upward tendency as the reach and popularity of our webinars was growing, and with a growing diversity of technical and policy experts with wide geographic range. HL7 Europe participated in the January, May and October HL7 FHIR Connectathons.

Key achievements: HL7® FHIR® IG for Laboratory Reports (EU realm): following ballot reconciliation, the TNT in February 2024 approved the publication of the HL7 FHIR IG STU 1 (EU REALM).

- Publications
 - [HL7 Europe Base and Core FHIR IG v1.0 \(R4 and R5\)](#)
 - [HL7 Europe Extensions FHIR IG v1.0 \(R4 and R5\)](#)
 - HL7 Europe [Laboratory Report FHIR Implementation Guide v1.1 \(R4\)](#)
- Ballots
 - [HL7 Europe Base and Core FHIR IG v2.0 \(R4 and R5\)](#)
 - HL7 Europe Medication Prescription and Dispense (R4 and R5)
 - Imaging Study Report (R5)
 - HL7 Europe Hospital Discharge Report (R4) ballot
 - New project approval HL7 Europe Common Cancer Model FHIR IG (R4)

In addition, there were several attended WGs for EHDS priority data categories. Participation in the GIDWG group for IDMP.

EU Funded Projects Update

HL7 Europe consistently secures grant funding from public funding sources in the European Union, such as the EU Horizon, IMI, and IHI, a testament to our robust network and collaborative spirit. We strategically align these grant-funded projects with our core objectives, ensuring our efforts directly contribute to the progress of healthcare IT and interoperability. The subsequent section details our current portfolio of both funded and unfunded initiatives.




Figure 1: Funded Projects 2011 - 2025



Gravitate Health - Empowering and Equipping Europeans with health information for Active Personal Health Management Adherence to Treatment

Making the most of health information for an optimal patient experience. The digitization of healthcare information has infinite benefits for clinicians, patients and their support network. When it comes to patient engagement, digital information tools can facilitate patients' journey by offering them access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context and literacy level. The EU-funded Gravitate-Health project aims to demonstrate how an integrated, digital, user-centric health information solution could enable tangible improvements in the availability and understanding of health information from a set of trusted sources. Moreover, Gravitate-Health will highlight how improved availability and understanding of health information can lead to better adherence to treatment, safer use of medication and improved health outcomes, and overall health-related quality of life. Key activities include a Hackathon in 2025, and the HIMSS interoperability showcase. Work has been instrumental for Vulcan Accelerator, ePI project, with participation in all HL7 FHIR Connectathons of 2025, participating also in the Global IDMP Working Group (GIDWG) meetings. Besides the formal HL7 International ePI HL7 FHIR IG, a second HL7 FHIR IG for the Gravitate Health G-lens is under preparation.

HL7 Europe Role: Interoperability lead, WP5 lead, and liaise with HL7 Working Groups (WGs), coordinate development of the [Gravitate-Health HL7® FHIR® Implementation Guide](#) for ePI co-lead Vulcan ePI project, ePI creator, server and [viewer](#) dedicated to the Gravitate-Health ePI services.

Funded under: Innovative Medicines Initiative 2 (IMI2) with Grant Agreement 945334. H2020-EU.3.1. Health, demographic change and well-being; H2020-EU.3.1.7.

Topic: IMI2-2019-18-03 - Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project

Duration: 1 November 2020 to 31 October 2025

Overall budget: € 18 561 750

EU contribution: € 9 280 000

Coordinated by: UNIVERSITETET I OSLO, Norway

Funding for HL7 Europe: €729 428,759

HL7 Europe Team: Joao Almeida (Product Owner), Giorgio Cangilioli, Catherine Chronaki (interoperability lead) and Henrique Martins (advisor), Rhonda Facile (communities), Kai Heitmann (Style Sheets, synthetic data)

Project Website: <https://www.gravitatehealth.eu>

For more information: <https://cordis.europa.eu/project/id/945334>



PanCareSurPass: PanCare studies of the scale-up and implementation of the digital Survivorship Passport to improve people-centred care for childhood cancer survivors

Hundreds of thousands of childhood cancer patients in Europe continue to have unique health issues as they grow. Their long-term follow-up care is critical, due to increased morbidity and mortality. Unfortunately, treating healthcare professionals often lack access to their past medical data.

The Survivorship Passport (SurPass) solution was designed to overcome this knowledge gap. In this context, the EU-funded PanCareSurPass project will scale up the SurPass and evaluate the implementation of a digital Survivor Passport in six European countries, considering various scenarios and issues. Work will result in a prediction model that will ease successful SurPass implementation across Europe.

The PanCareSurPass HL7 FHIR IG, sets the stage for analysis of care plans for Childhood cancer survivors. The team spearheaded several publications and created a FHIR startup guide to help people on board with the IG. We are still exploring collaboration with PanCare for further development of the FHIR IG and hope to continue aspects of the work under Hospitals on FHIR, sharing the experience from 5 hospitals and a registry across Europe.

- **HL7 Europe Role:** WP3 leader is the creation of an [HL7® FHIR® Implementation Guide](#) that will allow the semi-automatic creation of the Survivorship passport.
- **Funded under:** SOCIETAL CHALLENGES - Health, demographic change and well-being
- **Duration:** 1 March 2021 to 31 August 2025
- **Overall budget:** € 4 000 000.00
- **EU contribution:** € 4 000 000.00
- Coordinated by: UMC-Mainz
- Funding for HL7 Europe: € 346 875.00
- **HL7 Europe Team:** Roberta Gazzarata, Giorgio Canglioli (lead), Michael Strubin, Rhonda Facile, and Catherine Chronaki
- **Project Website:** <https://www.pancaresurpass.eu/>
- **For more information:** <https://cordis.europa.eu/project/id/899999>



xShare: Expanding the European EHRxF to share and effectively use health data within the EHDS

Digitalization of the healthcare sector, interoperability remains a persistent challenge. Fragmented systems hinder the seamless exchange of vital health data, impeding patient care and stifling research efforts. As such, GDPR obligations further complicate matters, as individuals struggle to navigate the complex landscape of data sharing consent. This EU-funded xShare project will develop an innovative button for health portals and patient apps that can be used to effortlessly share personal health data in compliance with the GDPR. xShare will establish common specifications and elements, fostering collaboration among stakeholders. From hospitals in Italy to national portals in Greece and Ireland, xShare promises a future of interconnected healthcare systems.

In 2025, xShare has contributed to the advancement of HL7 FHIR IGs (HL7 EU realm) for priority data categories, aligning with the xt-EHR project, under dual agreements between xShare and xt-EHR and the National Health Authority of Cyprus and HL7 Europe. The teams engaged in the work across Europe numbered more than 100 experts led by Giorgio Cangili, Rutt Lindstrom, Hynek Kruzic. Additionally, Kai Heitmann engaged in the creation of synthetic data in Sinderai. These and other resources produced by xShare partners are available as part of the x-Bundles, and will no doubt help early adopters implement the xShare button in patient facing apps, preparing the ground for the EHDS.

- **HL7 Europe Role:** Scientific coordinator and responsible for technical specifications.
- **Funded under:** EU-wide digital health solutions
- **Duration:** 1 December 2023 – 30 November 2026
- Overall Budget and EU contribution: € 7 803 632,50
- **Coordinator:** MedCom, DK
- Funding for HL7 Europe: € 346 875.00
- **HL7 Team:** Kai Heitmann, Hynek Kruzic, Giorgio Cangili, Rutt Lindstrom, Rhonda Facile, and Catherine Chronaki (lead).
- **Project Website:** <https://xshare-project.eu>
- **For more information:** <https://cordis.europa.eu/project/id/101136734/de>





NextGen: Personalised Medicine, Prediction, Prevention, Diagnosis, Treatment of Cardiovascular Disease

NextGen, is building novel and synergistic tools to enable portable multimodal, multiomic and clinically oriented research in high-impact areas of cardiovascular medicine. NextGen tools will benefit researchers, innovators and healthcare professionals by identifying and overcoming health data linkage barriers in exemplar use cases which are complex or intractable with existing technology. Consequently, it will benefit patients, providing faster diagnosis, and better treatments (including personal medicine). A comprehensive gap analysis of the existing landscape, factoring in ongoing initiatives will ensure NextGen deliverables are forward-looking and complementary.

In 2025, we had quite impactful session in DIA Europe in Bern and a paper accepted advancing the notion of a composite diversity index for multimodal data sets demonstrated through synthetic data. The work will continue in 2026 with the integration of this work to the NextGen pathfinder.

- **HL7 Europe Role:** Standards Update, policy, EHDS connection
- **Funded under:** NextGen project has received funding by the European Union's Horizon Europe, under grant agreement No 101136962; The British associated partners of NextGen were funded by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee [grant agreements No 10098097, No 10104323]; The Swiss Federation.
- **Duration:** 1 January 2024 – 31 December 2027
- Overall Budget and EU contribution: € 7 601 771,25
- **Coordinator:** UMC Utrecht
- Funding for HL7 Europe: €104.000
- **HL7 Team:** Catherine Chronaki (lead), Evangelia Anna Markatou, and Giorgio Cangilioli
- **Project Website:** <https://www.nextgentools.eu/personalised-medicine/>
- **For more information:** <https://cordis.europa.eu/project/id/101136962>





Protect-Child: Data integration for improved outcomes in child transplants

The EU-funded PROTECT-CHILD project aims to improve outcomes for children in need of liver or kidney transplantation by integrating high-throughput data from various sources. It focuses on developing a secure infrastructure, harmonising data standards, and assembling large datasets to enhance clinical outcomes. The project brings together a consortium of specialists in technology, data standardisation, clinical expertise, legal experts, patient representatives, and policymakers. It aims to enable the secure and compliant processing, analysis, and sharing of sensitive personal data while preserving privacy and security.

In 2025, work started on the Protect-Child HL7 FHIR IG (<https://build.fhir.org/ig/hl7-eu/protect-child/index.html>) which bridges FHIR and OMOP in paediatric transplantation, connecting data from the Peter Registry, clinical data from EHRs, and methodological genetic studies. Here we also examine bias, the other side of diversity, and relevant ideas were presented in the IEEE-EMBS BHI Workshop in Atlanta, in October.

- **HL7 Europe Role:** Development of HL7 FHIR IGs
- **Funded under:** Health
- **Duration:** 1 June 2024 – 31 December 2028
- **Overall Budget and EU contribution:** €8091327,50
- **Coordinator:** UNIVERSIDAD POLITECNICA DE MADRID
- **Funding for HL7 Europe:** €351 875.00
- **HL7 Team:** Catherine Chronaki (lead), Evangelia-Anna Markatou, and Giorgio Cangioli
- **Project Website:** <https://protect-child.eu>
- **For more information:** <https://cordis.europa.eu/project/id/101137423>



IDEA4RC: Intelligent Ecosystem to improve the governance, the sharing and the re-use of health Data for Rare Cancers

The EU-funded IDEA4RC project aims to establish an Artificial Intelligence (AI) assisted data ecosystem for Rare Cancers (RC) to enable access and the possibility to re-use existing health-related data from different sources. These include cancer registry data, electronic health records, electronic health care utilisation database across several European healthcare systems. The creation of the RC data ecosystem will increase understanding of these types of cancers and promote research and improve the quality of care for patients. The project will be executed within the framework of the European reference network for rare adult solid cancers (ERN EURACAN).

In 2025, the team spearheaded the work of the Common Cancer Model and created the IDEA4RC HL7 FHIR IG. The work has been fundamental in the establishment of the Phoenix Accelerator.

- **HL7 Europe Role:** creation of an [HL7® FHIR® Implementation Guide](#), common cancer model.
- Funded under: Health
- **Duration:** 1 September 2022 – 31 August 2026
- Overall Budget and EU contribution: € 8 190 468,13
- **Coordinator:** FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (Italy)
- Funding for HL7 Europe: € 346 875.00
- **HL7 Europe team:** Roberta Gazzarata, Luc Chatty, Catherine Chronaki, Rhonda Facile, and Giorgio Cangioli (lead)
- **Project Website:** <https://www.idea4rc.eu>
- **For more information:** <https://cordis.europa.eu/project/id/101057048/reporting>



FLUTE: Pioneering secure healthcare AI across borders

The FLUTE project will advance and scale up data-driven healthcare by developing novel methods for privacy-preserving cross-border use of data hubs. The focus is on improving predictions of aggressive prostate cancer through AI support to physician, while minimising unnecessary biopsies. The project will deliver a secure environment for federated healthcare AI solution development, testing and deployment, including the integration of real-world health data from the data hubs and the generation and utilisation of synthetic data. To demonstrate the practical use and impact of the results, the project will integrate the FLUTE platform with health data hubs located in three different countries, use their data to develop a novel federated AI toolset for diagnosis of clinically significant prostate cancer and perform a multi-national clinical validation of its efficacy. Led by INRIA (FR), the project will deliver results by 2026.

In 2025, besides creating and maintaining the Flute HL7 FHIR IG, the team has been very active in preparing the ground for the Phoenix, the HL7 Europe Cancer Initiative.

- **HL7 Europe Role:** HL7 Europe is responsible for the [HL7® FHIR® IG](#) and works on HL7® FHIR® Questionnaires and CQL applications.
- **Funded under:** HORIZON-HLTH-2022-IND-13-02 - Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation.
- **Duration:** 1 May 2023 – 30 April 2026
- Overall Budget and EU contribution: € 6 304 750,00
- **Coordinator:** INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET AUTOMATIQUE (France)
- Funding for HL7 Europe: € 258 750,00
- **HL7 Europe Team:** Luc Chatty, Catherine Chronaki, Rhonda Facile, and Giorgio Cangioli (lead)
- **Project Website:** <https://www.fluteproject.eu>
- **For more information:** <https://cordis.europa.eu/project/id/101095382>




One Aqua Health: Protecting Urban Aquatic Ecosystems to Promote One Health

OneAquaHealth aims to improve the sustainability and integrity of freshwater ecosystems in urban environments. By investigating the interconnection of ecosystem health and human wellbeing, the project will identify early warning indicators and enhance environmental monitoring with AI-assisted tools. As a result, the project will support decision-makers in finding adequate and timely decisions as well as effective measures to restore aquatic ecosystems health and promote OneHealth. As part of this work, the project has developed the **OneAquaHealth HL7 FHIR Implementation Guide**, providing a structured FHIR-based framework for data exchange between environmental sensors, health systems, and community platforms. The guide adopts HL7 FHIR to harmonize data from environmental monitoring systems, public health records, and community reporting platforms, enabling efficient aggregation and analysis across multiple domains. The guide defines a **unified indicator framework** for biological, hydro morphological, water-quality, bio-risk, and remote-sensing indicators, serving as the conceptual backbone of the OneAquaHealth data model. It ensures consistent semantics across domains, supports future extension as new indicator categories or methodologies are introduced, and provides machine-readable definitions that enable automated validation and integration into analytics pipelines. The work has also demonstrated an **end-to-end data pipeline**, from data collection to the publication of validated HL7 FHIR samples. Examples have been created for environmental and health-related measures from Gifyros and Almyros in Heraklion, Benevento, and Oslo. In total, the project has produced validated sample datasets covering 135 measures from Heraklion, 163 from Benevento, and 81 from Oslo, together with dataset metadata shared through 12 FHIR Library resources. A dedicated HL7 FHIR server has also been set up to publish and share these examples.

The project is a Research and Innovation Action funded under the Horizon Europe programme, led by the University of Coimbra (PT) from 2023 until 2026.

- **HL7 Europe Role:** To support the use of health data standards with the use of HL7® FHIR® (Fast Healthcare Interoperability Resources). The use of FHIR® enables the rapid transfer of information through the project’s various digital health and environmental monitoring tools in real time.
- **Funded under:** HORIZON-CL6-2022-GOVERNANCE-01-09 - Environmental observations solutions contributing to meeting “One Health” challenges
- **Duration:** 1 January 2023 – 31 December 2025
- Overall Budget: € 5 085 113,75
- **EU contribution:** € 4 939 558,00 EU HORIZON Grant agreement ID: 101086521
- **Coordinator:** UNIVERSIDADE DE COIMBRA (Portugal)
- Funding for HL7 Europe: € 400,000
- **HL7 Europe Team:** Gora Datta, Eleni Kokkinou, Stratos Kokolakis, Marilena Anastasaki, Catherine Chronaki (lead), and Giorgio Cangioli.
- **Project Website:** <https://www.oneaquahealth.eu>
- **For more information:** <https://cordis.europa.eu/project/id/101086521>



READI READI: Research in Europe and Diversity Inclusion

READI (Research in Europe and Diversity Inclusion) is a Horizon Europe and Innovative Health Initiative (IHI) project focused on improving diversity, equity, and inclusion in clinical research across Europe. The project aims to reduce barriers to participation and ensure that clinical studies better represent real-world populations through patient-centered approaches, digital innovation, and interoperable health data standards. Bringing together hospitals, research organizations, industry, patient groups, and standards bodies such as HL7 Europe and CDISC, READI supports the development of more inclusive, efficient, and trustworthy clinical research aligned with the future EHDS.



This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101166227. The JU received support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropeBio, MedTech Europe, Vaccines Europe, and Medicines and Healthcare Products Regulatory Agency and Breakthrough T1D. This project is also supported by UKRI (Research and Innovation) under grant agreement No 10152424 for National Institute for Health and Care Excellence and grant agreement No 31052024 for the University Court of the University

of Aberdeen.

- **HL7 Europe Role:** To support the READI project by advancing interoperability and standards-based approaches for inclusive clinical research. Its role focuses on promoting the use of HL7® FHIR® and related standards to improve the exchange and reuse of clinical study data, support the READI digital platform, and align the project with broader European initiatives such as the EHDS. HL7 Europe also contributes to standards coordination, stakeholder engagement, and sustainability activities to help ensure READI outputs are scalable and reusable beyond the project.
- **Funded under:** Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101166227
- **Duration:** 1 January 2025 – 31 December 2030
- Overall Budget: € 68 740 874,00
- **EU contribution:** € 31 538 000,00 EU HORIZON Grant agreement ID: 101166227
- **Coordinator:** SERVICIO MADRILENO DE SALUD, Spain
- Funding for HL7 Europe: € 362 450,00
- **HL7 Europe Team:** Catherine Chronaki (Lead) and Giorgio Cangiolì.
- **Project Website:** <https://ihi-readi.org/about-readi/>
- **For more information:** TBD



CAREPATH: Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health

CAREPATH aims to improve chronic disease management and medication persistence by transforming the care ecosystem, ensuring personalised support for better health outcomes, and reducing healthcare costs. We focus on improving medication adherence and persistence for three prevalent chronic conditions: Obesity (BMI \geq 30 kg/m²), Type 2 Diabetes Mellitus (T2DM), and cardiovascular diseases (CVD), including chronic heart failure (CHF), across six diverse European countries: Germany, Israel, the Netherlands, Poland, Spain, and Sweden. These countries represent various EU healthcare environments and economic statuses, emphasising the need for tailored approaches to patient care. The CAREPATH strategy involves integrating localised non-digital and digital health solutions to address the unique healthcare delivery challenges in each region. The CAREPATH toolbox collects, combines, and customises existing solutions into adaptable modules for broad application in both primary and secondary care settings. This toolbox will be tested in four studies across two settings in all six countries in both primary and secondary care. Three pilot studies in different regions as well as a proof-of-concept study in Germany will be conducted. This comprehensive evaluation, including HTA, aims to assess the toolbox's implementation and effectiveness, with a strong focus on learning what works for what groups of patients in which setting.

Recognizing the significant impact of obesity, particular emphasis is placed on treatment adherence and persistence of medications that facilitate weight loss, such as dual GIP/GLP-1 receptor agonists, but CAREPATH studies also include patients using lipid-lowering drugs, insulin, and SGLT2 inhibitors. Our goal is to empower patients by improving communication and data sharing among patients, healthcare providers, and other stakeholders, thereby supporting the entire ecosystem and alleviating the burden on healthcare systems. In 2025, the team has focused on the architecture and the data management plan

- **HL7 Europe Role:** HL7 Europe is responsible for the [HL7® FHIR® IG](#) and data management (WP6 co-lead) aligning and transferring lessons from Gravitate Health.
- **Funded under:** [HORIZON-JU-IHI-2024-06-01-two-stage - Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases](#)
- **Duration:** 1 May 2025 – 30 April 2030
- **Overall Budget and EU contribution:** € 11300000
- **Funding for HL7 Europe:** €409250
- **Coordinator:** RISE RESEARCH INSTITUTES OF SWEDEN AB
- **HL7 Europe Team:** Frank Ploeg (WP6 co-lead), Joao Almeida, Catherine Chronaki, and Giorgio Cangoli
- **Project Website:** <https://carepath-ihl.eu/>
- **For more information:** <https://cordis.europa.eu/project/id/101192133>



myHealth@myHands: Person-Centred Health Management through access to their health data using the EUDI Wallet Services

The myHealth@myHands project will help address the growing need for a unified data ecosystem across the European Union. Currently, accessing medical records and digital health services can be a challenge, especially when travelling between different EU countries. The project aims to help streamline this process by making medical records and health data interoperable and universally accessible by 2030.

A key aspect of myHealth@myHands is to empower citizens with the ability to manage their health data. The project also focuses on making health services more accessible through digital means, allowing for personalised health support and seamless integration with digital health services. This means that individuals will be able to manage who has access to their medical information, ensuring privacy and security.

By leveraging existing infrastructures and integrating with MyHealth@EU services, myHealth@myHands aims to improve the usefulness of data across Europe and make a significant contribution to the data foundation of the European Health Union. A knowledge hub will foster open dialogue with citizens, patients, health professionals, industry representatives, and academia to promote community collaboration and best practices.

myHealth@myHands aims to transform digital health by providing secure, user-friendly access to health data, ensuring that all EU citizens can benefit from a connected and efficient health ecosystem. The project runs from April 2025 until March 2029 and is coordinated by the Irish Department of Health.

- **HL7 Europe Role:** HL7 Europe will support the project with expertise on standards and interoperability, policy outreach, and communications.
- **Funded under:** <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/DIGITAL-2024-CLOUD-AI-06-HEALTHACCESS>
- **Duration:** 1 April 2025 – 31 March 2029
- **Overall Budget and EU contribution:** EUR 16,671,284, EU contribution EUR 8,335,632
- **Funding for HL7 Europe:** € 99 243
- **Coordinator:** Department of Health Ireland
- **HL7 Europe Team:** Giorgio Cangioli, Catherine Chronaki, Michael Strübin
- **Project Website:** <https://myhealthmyhands.eu/>
- **For more information:** <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/projects-details/43152860/101195425/DIGITAL>



i2X: Intelligent Implementations of the European EHR Exchange Format

The i2X project, led by Uphill, will connect electronic health record systems across Europe between 2025 and 2029 building on the Electronic Health Record Exchange Format. The goal is to enable seamless access and sharing of health data across borders, ensuring better healthcare for patients who travel or live in different EU countries. The project will also strengthen care coordination across the EU, making healthcare systems more resilient. Key benefits include reducing costs and inefficiencies caused by duplicate medical procedures and tests while minimising risks associated with missing clinical information.

In practice, the project aims to ensure that different health information systems used across Europe can communicate with each other, meaning they can store, exchange, and interpret health data using a common language.

The initiative will launch 35 pilot projects in five key areas: e-prescriptions, lab and test results, patient summaries, medical imaging, and discharge reports. A total of 12 EU Member States – including the Netherlands, Belgium, Cyprus, Czechia, Finland, France, Germany, Greece, Ireland, Italy, Portugal, and Spain- will participate. Most will run pilot projects, some incorporating Artificial Intelligence-based technologies.

i2X aims to support the digital transformation of healthcare systems by improving how health data is exchanged — both within national borders and in cross-border interactions with the EU — without adding burden to healthcare professionals. Through in-service testing at demonstration sites in 12 EU Member States, i2X will show how digital tools can enable better care, better outcomes, and a more connected health ecosystem.

Co-funded by the European Union, i2X contributes directly to the vision and goals of the EHDS and supports the rollout of MyHealth@EU services.

- **HL7 Europe Role:** Supporting role across the project, and task leader in Work Package 3 “EEHRxF Testing and Implementation Laboratory and Specifications”
- **Funded under:** <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/DIGITAL-2024-CLOUD-AI-06-HEALTHRECORD>
- **Duration:** 1 April 2025 - 31 March 2029
- **Overall Budget and EU contribution:** EUR 7,997,889, EU contribution EUR 3,993,059
- **Funding for HL7 Europe:** EUR 91,458
- **Coordinator:** Uphill
- **HL7 Europe Team:** Giorgio Cangioli, Catherine Chronaki, Michael Strübin
- **Project Website:** www.i2Xhealth.eu
- **For more information:** <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/projects-details/43152860/101195323/DIGITAL>

Key Initiatives

HL7 Europe Cancer Initiative



Cancer has a significant impact in Europe and globally, in terms of diagnosis and death numbers and economic costs. Updated strategies in cancer prevention, treatment, and care are needed. The European Union has responded to these needs with the "Europe's Beating Cancer Plan"

aimed to address cancer comprehensively through prevention, early detection, treatment, and improving patients' and survivors' quality of life. A Common (European) cancer data model, agnostic to the type of cancer, usable across different use cases was needed to support data sharing and assure sustainability.

In response, in 2024 the Phoenix HL7 Europe Cancer Initiative (following the principles for an HL7 FHIR Accelerator) was started comprising representatives from multiple projects and organizations collaborating in a neutral space with clear governance goals.

The Phoenix HL7 Europe Cancer Initiative is a multifaceted effort to improve the exchange and use of cancer-related data across Europe, aiming to enhance research, treatment, and ultimately, patient outcomes. It recognizes the critical need for interoperability in oncology data, bringing together various stakeholders like laboratories, clinicians, researchers, and registries to facilitate a learning health system. The vision is to move towards a future where seamless data interoperability transforms cancer care and research, enabling breakthroughs that improve patient outcomes and empower collaborative innovation across Europe

The Phoenix HL7 Europe Cancer Initiative will play a leading role in the development and adoption of European digital health standards for cancer to support cancer research and care delivery through interoperable data standards, by promoting a unified approach that enhances patient treatment, accelerates research, and closes the loop between care provisioning and research insights, aligning with and contributing to the EHDS initiatives and to foster a unified ecosystem where healthcare providers, researchers, and policymakers collaborate to enhance patient outcomes and accelerate innovation.

To achieve this vision, the primary goals are to Drive Consistency: ensure that healthcare data is consistently structured and interoperable across different systems and settings. Speed Up Implementation: accelerate the development of HL7 standards, particularly HL7 FHIR (Fast Healthcare Interoperability Resources), by focusing on specific clinical or administrative use cases. Foster Collaboration: bring together industry stakeholders to co-develop solutions that meet real-world needs and regulatory requirements. Ensure Relevance: tailor standards to address pressing needs in specialized areas, such as oncology, public health, or social determinants of health. The core team, which is an open group, currently includes representatives from Institut Paoli Calmettes (FR), Institut National du Cancer (FR), Berlin Institute of Health @ Charité (DE), Paris Saclay Cancer Cluster (FR) and Netherlands Comprehensive Cancer Organisation (IKNL) (NL).



Phoenix HL7 Europe FHIR Initiative Phases

The Phoenix project phases include Inception, Formation, Operational and Growth. The inception phase included validate that the proposed initiative and the evaluation of long-term viability, establishment of core founding member support (figure above) and confirmation of broad industry value. The Formation phase included SOU development and founding members have agreed and committed to funding and/or in-kind support. A Steering Committee was established to authorize spending and a PMO contract process was completed, and the on-boarding of members was commenced. The operational phase included the formation of a use case team to develop and deliver standards artifacts while engagement with HL7 work groups and community started to anchor the project across these teams and encourage participation. Outreach to broader a community to educate and promote the accelerator was also begun. We are now in the growth phase where operational activities are ongoing, these include identification and engagement with additional members, securing funding for new use case activities, maturation processes achieved for standards artifacts (IGs) and initiation of pilot projects, strengthen ties with the implementer community and management of growth and maturation processes.

PHOENIX Project Phases




Figure 2: Phoenix European Initiative Phases

The Phoenix 3 Year Plan – Major Objectives



Figure 3: Phoenix 3-year Plan

Common Cancer Data Model Project

The goal of the HL7 Common Cancer Data Model Project is to define a minimal, extensible, non-exhaustive European cancer data model that is agnostic to the type of cancer; usable across different use cases; leverages on the experiences of the European projects working with primary and secondary usage, considers the availability and usability of reliable data in the EHR systems and its HL7 FHIR representation in the form of a HL7 FHIR Implementation Guide. Design principles include inclusive and cross-cutting and applicable to cancer domains and purposes of use, considers the needs of different communities. To accomplish this an incremental approach has been adopted to focus on a minimal core set that can be extended or enhanced iteratively and purpose designed to facilitate representation in the HL7 FHIR exchange standard. Key benefits include an implementation independent data model (the cancer data set) accompanied by an HL7 FHIR Implementation Guide that includes HL7 FHIR logical models of the cancer model and HL7 FHIR profiles for ready implement of this core data set.

Collaboration and Cross Project Synergy

HL7 Europe has a strong track record of collaborating with various EU-funded projects and national initiatives in cancer research and data sharing. This extensive experience, including work with projects like IDEA4RC, OSIRIS, PanCareSurPass, FLUTE, INCISIVE, and the MEDOC dataset, helps us foster synergies and prevent fragmented efforts. Moving forward, HL7 Europe will partner with these groups and stakeholders and work towards aligning deliverables and ensuring that the emerging European Common Cancer Model and HL7 FHIR standards are usable across all relevant projects.

Phoenix also started a collaboration with mCode and CodeX to evaluate a possible joint work on a global Common Cancer Model.

HL7 Europe Facility



In 2024, the HL7 Europe Board of Directors approved the creation of the HL7 Europe facility and appointed Joao Almeida as responsible. The HL7 Europe Facility provides a comprehensive suite of tools and services to assist both current and potential users in understanding, testing, validating, and implementing HL7 EU standards and EU project specifications. The facility includes a set of sandboxes equipped with HL7 FHIR APIs, which enable users to experiment with storing, searching, and retrieving HL7 FHIR examples, as well as validating them. These sandboxes are often enhanced with dedicated plugins for displaying stored examples and managing associated questionnaires. In future, the sandboxes will be further supported by an HL7 FHIR Terminology Server, which will manage the terminology resources relevant to HL7 EU standards and EU project specifications. In 2025, the sandbox grew not only in service tooling but also in capability. To date, more than 36,644 visits have accessed the Facility. The HL7 Europe Sandbox provides access to HL7 Europe tools and sandboxes. The HL7 Europe tools and sandboxes are located here: <https://sandbox.hl7europe.eu>

Name	Description	Type
IG Uploader	Upload and manage Implementation Guides (IGs) using this API.	Tooling
FHIR Validator	Validate FHIR resources against profiles and rules	Tooling
IG Dependency Checker	Check dependencies for FHIR Implementation Guides.	Tooling
Uptime Checker	Monitor sandbox availability.	Tooling
Laboratory Sandbox	Platform for lab HL7 resources.	HL7 Eu Server
R4 Base Server	Play and test with all the r4 IGs developed by HL7eu	HL7 Eu Server
R5 Base Server	Play and test with all the R5 IGs developed by HL7eu	HL7 Eu Server
FHIR Questionnaire Viewer	View and interact with FHIR Questionnaires.	HL7 Eu Server
UNICOM Sandbox	UNICOM project testbed.	Project server
ePI Creator	Create and manage Gravitare ePI.	Project server
Gravitare-Health Server	ePI server for Gravitare-Health.	Project server
IDEA4RC Server	Play and test with IDEA4RC resources.	Project server
PanCareSurPass Project Server	Play and test with PCSP resources	Project server
FLUTE (sphinx) App	Access the FLUTE demo tool for Questionnaire data feed and decision support	Project server
FLUTE (legio) App	Access the FLUTE demo tool for Research Studies and Cohort/Datamart generation	Project server
FLUTE Server	Access to the FLUTE server for FHIR-related operations.	Project server
OneAquaHealth Server	Access the OneAquaHealth server for FHIR-related operations.	Project server

Table 1: HL7 Europe Facility tools and sandboxes

From a developer perspective, the deployment of these tools and resources was facilitated by compiling information and setting clear instructions regarding deploy and maintenance which was then tested during exchange of infrastructure provider, promoting a seamless exchange. For the future, it would be interesting to have a more robust way of upgrading IG content, especially for those in IGs development, creating a more useful way of testing specifications before release.

Joao Almeida

Chair, HL7 Portugal, HL7 Europe Board Member, Volunteer Manager of the HL7 Europe Facility

Hospitals on FHIR®



This community of practice is vital to the development of the European EHR Exchange Format spearheaded by the X-ehealth project and aims to promote the adoption of HL7® FHIR® within the European healthcare landscape, focusing on hospitals. HL7® FHIR® designed to be flexible and adaptable, making it easier to share data between different systems and organizations to help improve interoperability, healthcare and to drive innovation. <https://www.hospitalsonfhir.eu/home>

Membership and Country Ambassadors

At the close of 2025, our community consisted of 135 active members, our community continues to grow, with membership efforts ongoing in 2025.

HoF Ambassadors

HL7 Europe extends its sincere gratitude to our 12 dedicated Hospitals on FHIR Ambassadors, representing 8 countries: Luc Chatty and Frederik Laurent (France), Marie-Alexandra Lambot and Karlien Erauw (Belgium), Riccardo Haupt (Italy), Maria Bastos Salazar and Victor Costa (Portugal), Giuseppe Fico (Spain), Eugenia Rinaldi and Sylvia Thun (Germany), Anne Moen (Norway), and Justas Trinkunas (Lithuania). Thank you for your invaluable contributions!



HoF Events 2025



The third "Hospitals on FHIR® User Day" held 9-10 October 2025 in Berlin, Germany, represented significant growth, with ~35 in-person and remote attendees

The two-day agenda focused on a broad range of topics central to advancing interoperability in European healthcare. Key themes across the two days included FHIR implementation in real hospital environments; EHDS and EEHRxF readiness; Hospitals on FHIR® maturity and interoperability governance; patient engagement and citizen-controlled health data; the integration of clinical care and research; cybersecurity and modernization; the digital transformation of medical product information; and, finally, community building and ecosystem collaboration.

The event designed as a stakeholder and networking forum, featured Sponsor demonstrations, community roadmap sessions, a networking reception and collaboration across hospitals, vendors, standards organizations, researchers, and EU projects. Overall, the event positioned Hospitals on FHIR as:

- A European implementation community
- A practical deployment forum rather than a purely theoretical conference
- A bridge between standards, hospital operations, research, and policy
- A catalyst for EHDS-aligned digital transformation in hospitals

The programme reflects a transition from understanding FHIR to operationalizing FHIR at scale in European healthcare systems



Session Highlights

Rolling Out the Survivorship Passport to Hospitals: Standards, Interoperability and Implementation - PanCareSurPass



This session, held on day 1 of the HoF Berlin, User Days explored how the PanCareSurPass (PCSP) project is supporting the large-scale implementation of the digital Survivorship Passport (SurPass v2.0) across Europe to improve person-centred care for childhood and adolescent cancer survivors. Participants gained insight into the practical, technical, and policy considerations involved in integrating survivorship care plans into hospital systems using HL7 FHIR and interoperable digital health standards.

The session presented the PanCareSurPass Implementation Toolkit, HL7 FHIR Implementation Guide (IG), Quick Start Guide, and Implementation Checklist designed to help hospitals and healthcare IT teams begin adopting the Survivorship Passport within existing EHR environments. Speakers discussed lessons learned from pilot implementations across Europe, including interoperability challenges, mapping to clinical systems, and the importance of standards-based approaches for scalability and EHDS alignment.

In addition, the session highlighted how initiatives such as xShare and the EHDS can support patient-controlled access and sharing of survivorship information through standardized formats and the “Yellow Button” concept. Attendees left with a practical understanding of how survivorship care, HL7 FHIR implementation, and patient-centred digital health innovation can come together to support safer, more connected long-term follow-up care across Europe.



Digital Transformation of Medical Product Information in Hospitals – Gravitate-Health



The session, held on day 2, explored how Gravitate-Health’s electronic Product Information (ePI) and digital package leaflets are being implemented across Europe through Nordic pilots, and the German diGItal initiative. Speakers highlighted the growing use of HL7 FHIR-based ePI to provide structured, multilingual, and interoperable medicine information that can be integrated into hospital systems, pharmacy platforms, and patient applications. The presentations demonstrated how digital package leaflets can improve medicine availability, support safer use of medicines, and enable more personalized and context-aware information for both healthcare professionals and patients.

The session also featured a panel session with a patient advocate/representative who emphasized the communication benefits of digital medicine information within hospitals by ensuring clinicians, pharmacists, and nurses can access the same up-to-date information directly within clinical workflows. For patients being discharged from hospitals, digital ePI can provide easier access to understandable, personalized medicine information, helping improve treatment adherence, continuity of care, and confidence in managing medicines at home.

The Berlin Hospitals on FHIR event 2025 highlights the growing importance and adoption of FHIR as a key standard for achieving interoperability and advancing digital transformation in healthcare. The diverse range of topics covered underscores the multifaceted role FHIR plays in addressing current and future challenges in the healthcare ecosystem.

We extend our sincere gratitude to our Gold Sponsors, Intersystems and DMI, and our Silver Sponsor SRDC, and finally, our Bronze Sponsors, Eden Lab and okeiro, for their generous support of the event.



“2025 has continued to demonstrate strong growth and engagement across the Hospitals on FHIR community, reflecting the increasing importance of interoperability and digital transformation within European healthcare. Looking ahead, our focus remains on strengthening this momentum through expanded membership engagement, impactful User Days, and targeted workshops that support real-world hospital implementation of HL7® FHIR®. These activities play a vital role in advancing the European EHR Exchange Format, enabling EHDS readiness, and accelerating the adoption of interoperable, standards-based healthcare systems across Europe.” [Stefano Dalmiani, Co-Chair, Hospitals on FHIR, HL7 Europe, Board of Directors](#)



Hospitals on FHIR® European Network



Figure 4: Hospital on FHIR Network map

Hospitals on FHIR® Maturity Model

The Hospitals on FHIR® maturity model is a framework to determine the status of a hospital's HL7® FHIR® implementation status. It assigns a maturity level ranging from 0 (intention to work) to 10 (cross border data exchange). Benefits of Using the Model include:

- **Self-Assessment:** Hospitals can assess their current FHIR maturity level to identify strengths and weaknesses.
- **Goal Setting:** The model provides a clear roadmap for progressing towards higher maturity levels.
- **Benchmarking:** Hospitals can compare their progress to industry peers and best practices.
- **Education and Training:** Tailored educational resources can be developed based on the specific needs of hospitals at different maturity levels.
- **Community Building:** The model fosters collaboration and knowledge sharing among hospitals and other healthcare organizations.

By utilizing the Hospitals on FHIR® Maturity Model, hospitals can effectively navigate the complexities of HL7® FHIR® implementation and realize its full potential to improve patient care, enhance interoperability, and drive innovation in healthcare.




Figure 5: Hospitals on FHIR® Maturity Model

For more information on HoF events, recorded webinars and presentations visit: <https://www.hospitalsonfhir.eu/events>

Hospitals on FHIR® Governance

Current HoF Co-Chairs are Maria Bastos Salazar (CIO, ULSS Antonio Porto, Portugal) and Stefano Dalmiani (CDO, FTGM, Italy). The Terms of Reference were updated to provide guidance for members of HoF. (<https://www.hospitalsonfhir.eu>).

HL7 Europe expresses sincere appreciation to the HoF Steering Committee for their vital support and active engagement, which were instrumental in the success of the Hospitals on FHIR® User days.



HL7 Europe Working Group Meetings 2025



HL7 Europe held two Working Group Meetings in 2025: the first took place from 10–14 February in Lisbon, Portugal, and the second from 1–5 December in Cologne, Germany. Both meetings brought together experts, implementers, and community members to advance HL7 Europe FHIR specifications, terminologies, and related interoperability work for the EHDS.



The **Lisbon** meeting was hosted at ISCTE – University Institute of Lisbon and combined the Working Group Meeting with an EU-a-thon focused on HL7 Europe FHIR specifications and terminologies. The programme included collaborative discussions on use cases, verification of implementation guides, refinement of the FHIR specification, exchange of implementation experience, and

breakout working sessions. Major tracks included the European Hospital Discharge Report and Patient Summary, the European Common Cancer Model, the European Laboratory Report, Medication Prescription and Dispense, the European Imaging Study Report, and Analytics on FHIR.

The Lisbon event also featured the opening ceremony, presentations by HL7 affiliates, and a networking reception, strengthening collaboration across the European HL7 community. Links

- HL7 Europe’s BLOG about the event <https://www.hl7europe.org/a-fruitful-week-in-sunny-lisbon-hl7-europe-working-group-meeting-and-eu-a-thon-2025/>
- HL7.tv’s VLOG at <https://hl7.tv/hl7euwgm-vlog-lisbon.html>





The **Cologne** Working Group Meeting, held at Hotel Dorint An der Messe, continued the effort to shape the future of FHIR in Europe through topics such as HL7 FHIR specifications for the EHDS like work on the EU CORE profiles, the European Patient Summary, Laboratory Report,

Discharge Report, Medication, and the Imaging Report. Hands-on and tutorials, testing and refinement, and views on HL7 Europe initiatives and projects such as MyHealth@MyHands, xShare, Hospitals on FHIR and Gravitare Health completed the program. HL7 Germany's FHIR and Terminology Community Day was also embedded in the conference, showing for example that terminology alignment was part of their technical agenda.

This 3rd Working Group Meeting brought 160 individual participants to pre-Christmas Cologne, making it one of the larger HL7 Europe in-person community gatherings.

We encountered a clearer momentum towards the EHDS and the European EHR Exchange Format and HL7 Europe framed the meeting as part of its broader strategy to mature specifications and support harmonised interoperability across Europe.

Links

- HL7 Europe's BLOG about the event with presentations and material <https://hl7europe.eu/hl7-europe-working-group-meeting-2025-cologne/>
- HL7.tv's VLOG at <https://hl7.tv/hl7euwgm-vlog-cologne.html>

Together, the 2025 WGMs demonstrated HL7 Europe's continued momentum in convening the community around shared specification work, practical implementation challenges, and the evolution of interoperable digital health solutions across Europe.

Dr. Kai U. Heitmann
CEO, HL7 Germany,
Community Events Manager, HL7 Europe

Participation in HL7®FHIR® Accelerators

HL7®FHIR® Accelerator Vulcan: Connecting Clinical Research to Health Care




Under the umbrella of the EU Gravitate-Health project and in close collaboration with regulatory agencies including the European Medicines Agency, US FDA and the Japan PMDA. Key initiatives include the Vulcan electronic Product

Information (ePI) eLabeling project which was formed to develop a global IG for ePI in collaboration with the EU funded Gravitate-Health Project and other stakeholders. (<http://www.hl7.org/vulcan/>)

HL7 Europe co- organized the first EuroVulcan meeting in March 2023 in Paris, France. This meeting was well attended by industry, academia and regulators. It was followed by the EuroVulcan2 event in Athens which concentrated on "Regulatory Policy Development and Agile HL7 FHIR Implementation in Europe and Worldwide," on January 16, 2024.

In 2025, Vulcan collaborated with TEDHAS2 for the stakeholder event in Copenhagen, October 9, 2025. HL7 Europe assisted in the organization and held a panel where we focused on IPS+, and the need to prepare healthcare facilities for EHDS, while advancing their capability to support clinical trials. HL7 Europe participation in Gravitate-Health, xShare, and READI was highlighted.



Advising, Collaboration, and Liaison Activities

Liaison CEN/CENELEC Technical Committee 251



HL7 Europe continues to collaborate with CEN/CENELEC and CEN TC251 committee. In the context of this collaboration, it has established a liaison relationship and participates in the biannual meetings of the organization.

European Federation for Medical Informatics (EFMI)




HL7 Europe and EFMI Collaboration: HL7 Europe works closely with EFMI, the European Federation for Medical Informatics. (www.efmi.org). We actively participate in Medical Informatics Europe, the EFMI Flagship conference each year, the annual AMIA Conference, and MedInfo, IMIA global conference.



#AMIA2025

In 2025, HL7 Europe contributed to the following panels and workshops in Medical Informatics Europe, 2025:

- Towards EHDS Compliance in Europe to Support Public Health
- Computable biomedical knowledge to activate European learning health systems
- Inclusion Health Informatics
- Advanced Technologies for Logging and Sharing Health Data
- Leveraging the EHDS for advancing Public Health





HL7 Europe was in MedInfo2025 in Taipei, Taiwan and the keyword was collaboration:

- Empowering Patients through Digital Health: Innovative Solutions and Collaborative Strategies in a Transforming Landscape
- Preliminary Results from using Gen-AI to personalize Medication Leaflets, Joao Almeida
- Reimagining Standards Implementation to Advance Semantic Interoperability, Rhonda Facile, Catherine Chronaki, Becky Kush
- Workshop on Empowering Citizens with Care Plans and the xShare Button in the EHDS, Anne Moen, Morten Bruun Rasmussen, Catherine Chronaki
- Expressing Diversity of Health Datasets in the EHDS, Liliika Markatou
- xShare-powered Personal Digital Twins: End of Privacy or key to Precision Health?

We met there with the HL7 leadership, Dan Vreeman and Charles Jaffe. All in all MedInfo2025 was all about FHIR.

eHealth Stakeholders Group (eHSG)



HL7 Europe was part of the European Commission eHealth Stakeholders Group 2020-2026. Catherine Chronaki, represents HL7 Europe in the eHSG.

Advisor to NFDI4Health



The mission of NFDI4Health is to provide new opportunities for the scientific use of personal health data while respecting privacy requirements. Based on the Findable, Assessable, Interoperable, Reusable (FAIR principles¹) services are provided to researchers to permanently store, semantically enrich and share data in interoperable form and to merge data from different sources. Catherine Chronaki is in the advisory group of NFDI4health.

Summary of 2025

Communications and Outreach 2025

Profile view highlights



Date for 16/1/2025 - 31/12/2025






Source – LinkedIn Analytics

Metrics	
Impressions	214,881
Reactions	5,504
Comments	192
Reposts	159

Visitors	
Page Views	2,205
Unique Visitors	1,203

Followers	
New Followers	1,879
Total Followers	3,352





Conclusions:

- LinkedIn continued to serve as HL7 Europe’s most visible and high-performing communication channel.
- The account grew by nearly 1,900 followers in 2025 alone, with consistently high post engagement driven by event and standards-related content.

BlueSky

2025 Overall Stats – Source BlueSky Analytics

Statistics	
Total Followers	99
Total Shares	21



Total Likes	49
Number of Posts	31

<https://web-cdn.bsky.app/profile/hl7europe.bsky.social>

Mailchimp

Email Marketing



2025 Overall Stats – Source Mailchimp Analytics

Statistics	
Total Subscribers	166
Avg. Open Rate	40.7%
Avg. Clicks	9.5%
Nr. of emails (Dec)	1

Website visit highlights

2025 Overall Stats – Source Website Analytics

Statistics	
Total Page Views	43,131
Total Sessions	32,132
Number of Posts	39




Conclusions:

- The website has become a central repository for technical, event-related, and project content.
- The site continued to attract strong year-round interest, especially during high-visibility campaigns.

Website Improvements

HL7 Europe – European Projects’ webpage



At HL7 Europe projects webpage, we have developed a structured and dynamic mapping of European projects and initiatives connected to interoperability, digital health, standards implementation, and the EHDS.

This mapping serves as a central reference point for showcasing how [HL7 Europe](#) actively contributes to and collaborates across the European digital health ecosystem. By bringing together EU-funded projects, strategic initiatives, and interoperability-driven activities in one place, we aim to enhance visibility, foster collaboration, and support knowledge exchange among stakeholders across Europe.

The mapping approach focuses on:


- Identifying projects aligned with HL7 standards, interoperability frameworks, and health data exchange initiatives
- Highlighting synergies between projects, institutions, and European policy priorities
- Creating an accessible overview of ongoing innovation and implementation efforts
- Supporting stakeholders in discovering collaboration opportunities and shared objectives
- Demonstrating the growing role of standards-based interoperability within the European healthcare landscape

The webpage is continuously updated to reflect the evolving ecosystem of projects and initiatives in which HL7 Europe and its community are engaged.

In 2025, several improvements were implemented across the [HL7 Europe website](#) to enhance the visibility, accessibility, and management of events and community activities.

The Events page was restructured to clearly separate Upcoming Events from Past Events, improving navigation and allowing visitors to more easily identify current and completed activities. A category-based filtering menu was also introduced, enabling users to browse content more efficiently. Upcoming events are now highlighted at the top of the page with enhanced visual emphasis to increase engagement and visibility.

HL7 Europe - Event Highlights



The homepage Events section was aligned with the same structure, creating a more consistent user experience throughout the website. In addition, direct navigation links were added to both the Events and News sections, encouraging visitors to explore the full range of available content.


To further support event promotion and registrations, targeted popup notifications were introduced for selected events, including the WGM event campaign. These popups were displayed only to new visitors and achieved engagement rates significantly above standard newsletter benchmarks, contributing to increased traffic to registration pages and improved

event visibility.

A simplified event management workflow was also established, allowing events to be easily transitioned from Upcoming to Past Events categories after completion. Supporting draft content and placeholder visuals were additionally prepared to maintain an active and engaging appearance on the website, even during periods without scheduled events.

All updates were designed with flexibility in mind, allowing rapid adjustments or reversals whenever required, while contributing to a more dynamic, user-friendly, and engaging digital presence for the HL7 Europe community.

HL7 Europe – Scientific Publications section



Also in 2025, a dedicated Scientific Publications section was introduced on the [HL7 Europe website](#) to improve the visibility and accessibility of scientific publications associated with HL7 Europe activities and European collaborative projects. Developed with the support of Rhonda and Michael, the new [Articles page](#) provides a centralized and structured repository where visitors can explore published scientific work connected to the organization's initiatives and projects.

To enhance the user experience and facilitate easier browsing, each article entry includes an interactive preview feature, allowing visitors to click on the article image to view a first-page preview before accessing the full publication. In addition, direct links to the official publication pages have been incorporated, enabling users to seamlessly access the original scientific sources and publication platforms.

As part of the broader content integration strategy, identified scientific articles have also been connected directly to their respective project pages across the website. This approach strengthens the relationship between project activities and their scientific outputs,

providing visitors with a more comprehensive understanding of each initiative's impact and research contributions. For example, publications related to [PanCareSurPass](#) are now directly showcased within the project's dedicated webpage.

These additions contribute to a more knowledge-driven and interconnected digital ecosystem for HL7 Europe, further supporting dissemination, scientific visibility, and stakeholder engagement across the European health interoperability community.

HL7 Europe Governance

Organizational Structure

The following figure shows the current organizational chart of HL7 Europe, showing the connections between the HL7 International Board of Directors, the HL7 Europe Board of Directors, the Technical Coordination Team, and the European Advisory Council. It also lists the members of the HL7 International Board of Directors and the members of the Board of HL7 Europe.




Figure 6: HL7 Europe Organizational Chart 2025

HL7 Europe Board of Directors 2025 - 2026:

1. Jan-Eric Slot CIP, MD, MBA, MSc, HL7 Netherlands, Chair
2. Joao Almeida, PharmD, Msc, PhD, HL7 Portugal, Secretary
3. Roman Radomski, MD, MDA, HL7 Poland, Treasurer
4. Catherine Chronaki, Secretary General, Admin Delegate, Greece*
5. Giorgio Canglioli, PhD., Technical Lead***, Italy (EC)*
6. Bente Cecile By Jansen, Cand. Pharm, Norway
7. Tapani Piha, MD (FI)
8. Stefano Dalmiani (IT)
9. Julia Skapik, MD, MPH, USA, HL7 International
10. W. Edward Hammond, PhD, FHL7, USA, HL7 International
11. Andrew Truscott, FHL7, HL7 International, UK
12. Charles Jaffe, MD, PhD, FHL7, CEO, HL7 International, USA (EC)*

13. Karen Van Hentenryck, Ex Admin Director, HL7 International, USA (EC)*

* Board members who also serve on the **HL7 Europe Executive Committee**.

European Technical Coordination Team

Technical Coordination Team (TNT) supports the HL7 Europe goals by facilitating the technical collaboration among affiliates and experts, promoting capacity building and developing European standards, IGs, educational materials and other documents to support the HL7 Europe mission and goals.




Figure 7: European Technical Coordination Team (2025)

Communications Task Force

The Communications Task Force was formed after an inaugural meeting at the WGM in Athens in January 2024 with the purpose to advance communications and visual presence, with a focus on a website, a newsletter and mailing list, webinars and social media. Chaired by Line Andreassen Sæle (HL7 Norway), Task Force members came predominantly from affiliates in Germany, Netherlands, Italy, Portugal, and Switzerland.

Building on the launch of the HL7 Europe website in November 2024 (www.hl7europe.org), in 2025 the Task Force worked on refining the website content, on integrating the website with social media and newsletter, and on further promoting HL7 Europe's events and activities. Towards the end of the year, the Task Force successfully merged the website on the hl7europe.org domain with the hl7.eu domain.

European Standardization Projects under the EU Realm

In 2025, TNT and project teams continued the successful work on the following standardization projects, confirming the large engagement of the community:

- Base and Core Profiles
- Extensions
- Medication Prescription and Dispense
- European Patient Summary
- Hospital Discharge Report
- Laboratory Report
- Imaging Study Report

During this period the following results have been obtained:

- Publications
 - [HL7 Europe Base and Core FHIR IG v1.0 \(R4 and R5\)](#)
 - [HL7 Europe Extensions FHIR IG v1.0 \(R4 and R5\)](#)
 - HL7 Europe [Laboratory Report FHIR Implementation Guide v1.1 \(R4\)](#)
- Ballots
 - [HL7 Europe Base and Core FHIR IG v2.0 \(R4 and R5\)](#)
 - HL7 Europe Medication Prescription and Dispense (R4 and R5)
 - Imaging Study Report (R5)
 - HL7 Europe Hospital Discharge Report (R4) ballot
 - New project approval HL7 Europe Common Cancer Model FHIR IG (R4)

A collaboration with IHE Europe to work on joint projects was established - the Euridice initiative.

In this context:

- A procedure for Joint HL7 Europe / IHE Europe publications has been released
- A first joint project started: the [EU Health Data API FHIR IG \(R4\)](#)
- A joint group working on the imaging domain involving the Imaging Study Report FHIR IG and the IHE MADO profile created.

European Advisory Council

The Chairs of the European Affiliate Members of HL7 International, or their designated representatives, comprise the European Advisory Council.

HL7 Affiliate Member	Chair	HL7 Member	Affiliate	Chair
HL7 Austria	Stefan Sabutsch	HL7 Poland		Roman Radomski
HL7 Belgium	José Costa Teixeira	HL7 Portugal		João Almeida
HL7 Croatia	Miroslav Koncar	HL7 Romania		Andrei Vasilateanu
HL7 Czech Republic	Karel Zvara	HL7 Russia		Sergey Shvyrev
HL7 Denmark	Thea Mentz Soerensen	HL7 Slovakia		Eva Sabajova
HL7 Finland	Jari Porrasmaa	HL7 Slovenia		Brane Leskosek
HL7 France	Nicolas Riss	HL7 Spain		Francisco Perez
HL7 Germany	Sylvia Thun/Danny Ammon	HL7 Sweden		Bjorn-Erik Erlandsson
HL7 Greece	Panagiotis Bamidis	HL7 Switzerland		Roeland Luykx
HL7 Italy	Stefano Lotti	HL7 UK		Ben McAlister
HL7 Netherlands	Jan-Eric Slot	HL7 Ukraine		Leonid Stoyanov
HL7 Norway	Line Saele			

Table 2: European Advisory Council (2025)

Affiliate Map




Figure 8: Map of HL7 Europe Affiliates

Treasurer Report



The HL7 Europe budget for 2025, as approved by the Board of Directors on December, the 8th 2024, assumed the total expendable income for all office operations of € 278 900 and the total expenses for those activities of € 286 000.

The actual income was slightly smaller, due to the lack of HL7 International contributions, that were received in previous years and also budgeted for 2025. The main source of income in 2025 was as usual overhead contributions from the projects that HL7 Europe took part in. It was significantly higher than in the previous year and it seems that the project

overheads will remain the main source of income in the future.

The actual expenses for HL7 Europe office were almost 50% lower than budgeted. It resulted in significant operating income of € 95 252 instead of the minimal loss that was budgeted for 2025. There were two main reasons for that: careful spending on the office operations due to the uncertainty of how multi-year European projects would be going and lower than predicted actual project-related expenses in 2025. It should be expected that some of those expenses would shift to year 2026.

The cashflow in all 2025 was safe, offering good operating capital during the year. But it should be taken into account that relying on project overheads as the only actual source of income for HL7 Europe is a risk and Board of Directors should explore new, additional ways of funding in the future years.

Roman Radomski, Chair HL7 Poland, Treasurer HL7 Europe, 2025-2026

Financial Report

HL7 Europe Annual Results 2025




Figure 9: Annual Results 2011-2025

Annual Accounts Statement 2025

N°	0826312613	ABR-NPI 3.1
----	------------	-------------

ANNUAL ACCOUNTS

BALANCE SHEET AFTER APPROPRIATION

	Notes	Codes	Period	Preceding period
ASSETS				
FORMATION EXPENSES		20		
FIXED ASSETS		2108	<u>2.730</u>	<u>2.730</u>
Intangible fixed assets	6.1.1	21		
Tangible fixed assets	6.1.2	2207		
Land and buildings		22		
Plant, machinery and equipment		23		
Furniture and vehicles		24		
Leasing and other similar rights		25		
Other tangible fixed assets		26		
Assets under construction and advance payments		27		
Financial fixed assets	6.1.3	28	2.730	2.730
CURRENT ASSETS		2908	<u>1.354.779</u>	<u>1.745.753</u>
Amounts receivable after more than one year		29		
Trade debtors		290		
Other amounts receivable		291		
Stocks and contracts in progress		3		
Stocks		3006		
Contracts in progress		37		
Amounts receivable within one year		4041	337.510	252.168
Trade debtors		40	337.510	252.168
Other amounts receivable		41		
Current investments		5053		
Cash at bank and in hand		5456	1.009.322	1.487.905
Accruals and deferred income		4901	7.947	5.680
TOTAL ASSETS		2056	<u>1.357.509</u>	<u>1.748.483</u>

N°	0826312613	ABR-NPI 3.2
----	------------	-------------

	Notes	Codes	Period	Preceding period
EQUITY AND LIABILITIES				
EQUITY		1015	698.984	615.559
Association or foundation Funds	6.2	10	813	813
Revaluation surpluses		12		
Allocated funds	6.2	13		
Accumulated profits (losses)	(+)(-)	14	698.171	614.746
Investment grants		15		
PROVISIONS AND DEFERRED TAXES				
Provisions for liabilities and charges	6.2	16		
Pensions and similar obligations		160/5		
Taxation		160		
Major repairs and maintenance		161		
Environmental obligations		162		
Other liabilities and charges		163		
Provisions for grants and legacies to reimburse and gifts with a recovery right		164/5		
Deferred taxes		167		
		168		
AMOUNTS PAYABLE		17/49	658.525	1.132.924
Amounts payable after more than one year	6.3	17		
Financial debts		170/4		
Credit institutions, leasing and other similar obligations		172/3		
Other loans		174/0		
Trade debts		175		
Advances received on contracts in progress		176		
Other amounts payable		178/9		
Amounts payable within one year	6.3	40/48	223.267	283.773
Current portion of amounts payable after more than one year falling due within one year		42		
Financial debts		43		
Credit institutions		430/8		
Other loans		439		
Trade debts		44	223.267	274.111
Suppliers		440/4	223.267	274.111
Bills of exchange payable		441		
Advances received on contracts in progress		46		
Taxes, remuneration and social security		45		
Taxes		450/3		
Remuneration and social security		454/9		
Other amounts payable		48		9.662
Accruals and deferred income		492/3	435.258	849.151
TOTAL LIABILITIES		10/49	1.357.509	1.748.483

PROFIT AND LOSS ACCOUNT

	Notes	Codes	Period	Preceding period
Operating income and charges				
Gross operating margin	(+/-)	9900	100.870	-36.165
Of which non-recurring operating income		76A		
Turnover		70		
Contributions, gifts, legacies and grants		73		
Raw materials, consumables, services and other goods		6061		
Remuneration, social security costs and pensions	(+/-)	62		
Depreciation of and other amounts written off formation expenses, intangible and tangible fixed assets		630		
Amounts written off stocks, contracts in progress and trade debtors: Appropriations (write-backs)	(+/-)	6314		
Provisions for liabilities and charges: Appropriations (uses and write-backs)	(+/-)	6359		
Other operating charges		6408		
Operating charges carried to assets as restructuring costs	(-)	649		
Non-recurring operating charges		66A		
Operating profit (loss)	(+/-)	9901	100.870	-36.165
Financial income	6.4	7576B	3.884	31.798
Recurring financial income		75	3.884	31.798
Non-recurring financial income		76B		
Financial charges	6.4	6566B	21.329	
Recurring financial charges		65	21.329	
Non-recurring financial charges		66B		
Gain (loss) for the period before taxes	(+/-)	9903	83.425	-4.367
Transfer from deferred taxes		780		
Transfer to deferred taxes		680		
Income taxes	(+/-)	6777		
Gain (loss) of the period	(+/-)	9904	83.425	-4.367
Transfer from untaxed reserves		789		
Transfer to untaxed reserves		689		
Gain (loss) of the period available for appropriation	(+/-)	9905	83.425	-4.367

APPROPRIATION ACCOUNT

		Codes	Period	Preceding period
Profit (loss) to be appropriated	(+)(-)	9908	698.171	614.746
Gain (loss) of the period available for appropriation	(+)(-)	(9905)	83.425	-4.367
Profit (loss) brought forward	(+)(-)	14P	614.746	618.113
Withdrawals from capital and reserves		791		
Appropriations to allocated funds		691		
Profit (loss) to be carried forward	(+)(-)	(14)	698.171	614.746

Statement of Certified Accountant 2025

DocuSign Envelope ID: 7839EBF8-EE15-8738-811B-B85051ECD93D



Moore Audit

Schallinstraat 3
B-2000 Antwerpen

T +32 3 210 91 50

www.moore.be

INDEPENDENT REPORT OF THE AUDITOR REGARDING THE LIMITED REVIEW OF THE ANNUAL ACCOUNTS OF THE YEAR ENDED AS PER DECEMBER 31, 2025 OF HL7 EUROPE PRIVATE FOUNDATION

We have carried out a limited review on the financial statements of HL7 Europe Private Foundation ("HL7 International"), established at Square de Meeûs 38-40 in 1000 Brussels (company number 0826-312-613), for the period of 1st January 2025 till 31st December 2025, drawn up on the basis of the accounting reference system applicable in Belgium, with a balance sheet total per 31st December 2025 of EUR 1.357.509,62 and whose income statement closes with a profit for the financial year of EUR 83.424,48.

The preparation of the annual accounts is the responsibility of the governing body of HL7 Europe.

The responsibility includes, among other things: establishing, implementing and maintaining internal control over the preparation and fair representation of the financial statements that are free from material misstatement due to fraud or error, choosing and applying appropriate valuation rules, and making accounting estimates that are reasonable under the circumstances.

Our review is carried out in accordance with the standards of the Royal Institute for Auditors. These professional standards require that our review be organized and conducted in such a way as to obtain reasonable assurance that the financial statements do not contain material misstatements.

In accordance with these standards, we have taken into account the administrative and accounting organization of the association, as well as the procedures of internal control.

The governing body of the foundation has answered our questions for further clarification or information. On the basis of samples, we examined the justification of the amounts included in the submitted balance sheet and income statement.

An independent member firm of Moore Global Network Limited
members in principal cities throughout the world

Moore Audit BV: D&DC, DePloeyde 1 bus 96, 1000 Brussel
ORF Brussel • BTW: 02045 205 059



During our work, no significant deviations were found in which the operating costs were insufficiently accounted for by supporting documents and where these operating costs were not spent on other than the actual purposes of the foundation.

We have reviewed the valuation rules, the meaningful accounting estimates that the foundation made and the presentation of the balance sheet and income statement. We believe that our work provides a reasonable basis for expressing our opinion.

In conclusion, we declare that based on our limited review of the financial statements as of 31st December 2025 of HZ7 Europe, we are not aware of any material misstatements that would distort the true and fair view of the financial statements prepared by the foundation.

Antwerp, 5th May 2026

Guy Franken

Guy Franken
Legal Auditor

Certificate Of Completion

Envelope Id: 7839EBF8-EE15-8738-811B-B85061ECD93D	Status: Completed
Subject: Complete with Docusign: 280905.audit report HL7.pdf	
Source Envelope:	
Document Pages: 2	Signatures: 1
Certificate Pages: 2	Initials: 0
AutoNav: Enabled	Envelope Originator: Guy Franken
Envelope Stamping: Enabled	Explained: 1
Time Zone: (UTC+01:00) Brussels, Copenhagen, Madrid, Paris	Brussels, Brussels Hoofdstedelijk Gewest: 1020
	guy.franken@moore.be
	IP Address: 88.17.235.38

Record Tracking

Status: Original	Holder: Guy Franken	Location: DocuSign
5/5/2026 4:45:24 PM	guy.franken@moore.be	

Signer Events

Guy Franken
guy.franken@moore.be
Partner

Security Level: Email, Account Authentication (None), Digital Certificate

Signature Provider Details:

Signature Type: Itsmc - EU Qualified
Issuer: Intsig Group EU Qualified Electronic Signature CA G2
Subject: CN=Franken Guy Ludovius L

Signature

Signature Adoption: Pre-selected Style
Using IP Address: 88.17.235.38

Certificate policy:
[1]Certificate Policy:
Policy Identifier=1.3.6.1.4.1.48960.1.1.1.9.2
[1,1]Policy Qualifier Info:
Policy Qualifier Id=CPS
Qualifier:

<https://www.intsiggroup.com/en/documents/>

[2]Certificate Policy:
Policy Identifier=0.4.0.194112.1.2
[3]Certificate Policy:
Policy Identifier=1.3.76.16.6

Timestamp

Sent: 5/5/2026 4:45:55 PM
Viewed: 5/5/2026 4:46:28 PM
Signed: 5/5/2026 4:47:06 PM

Electronic Record and Signature Disclosure:
Not Offered via Docusign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	5/5/2026 4:45:55 PM
Certified Delivered	Security Checked	5/5/2026 4:46:26 PM
Signing Complete	Security Checked	5/5/2026 4:47:06 PM
Completed	Security Checked	5/5/2026 4:47:06 PM

Payment Events	Status	Timestamps
-----------------------	---------------	-------------------

HL7 Europe's Future Outlook

HL7 Europe is strategically positioned to strengthen the HL7 EU realm and expand its impact. Our strengthened core team will work closely with the HL7 Community in Europe to develop HL7® FHIR® IGs, specifications and educational material that address and support specific European healthcare requirements and correct implementation, guided by the Technical Coordination Team (TNT) chaired by Giorgio Cangioli, HL7 Europe Technical Lead.

HL7 Europe also plans to support healthcare facilities, startups and SMEs, as resources allow, to further accelerate HL7® FHIR® implementation across Europe by supporting with key initiatives within EHDS, most notably the myHealth@EU and HealthData@EU infrastructures. HL7 Europe in collaboration with HL7 Affiliates in Europe commits to support the EHDS with robust HL7 FHIR specifications in the EU realm. In this context the xShare project and our engagement with the xt-EHR and TEDHAS2 joint actions are expected to play a key role. Our support to the community will be demonstrated by investing reserves to develop an environment where interested individuals can work and explore HL7 FHIR IGs and specifications that HL7 Europe has developed in the context of EU funded research projects.

The third Hospitals on FHIR® User Days event in Berlin, Germany, achieved significant success, drawing participants both in person and online. That event garnered significant attendance, robust industry backing, and earned overwhelmingly positive feedback regarding its content—especially the clinical implementation use cases—and the networking it facilitated.

In 2025, HL7 Europe continued to support and grow FHIR adoption in European healthcare, focusing on hospitals and will continue to grow the Hospitals on FHIR® initiative, attracting more membership and activating national and regional chapters. We also saw strong continued focus on close collaboration with HL7® FHIR® Accelerator [Vulcan](#) and will partner with global SDOs and regulatory authorities to bridge the gap between healthcare and clinical trials. By streamlining data exchange and interoperability between healthcare and clinical trials data, we anticipate significant benefits for EU citizens, including faster drug approvals and swift access to innovative treatments and therapies. HL7 Europe continues to work towards enhancing the future of digital healthcare and will continue to collaborate with the European Federation for Medical Informatics (EFMI) to shape the education of young professionals, striving to support women in health informatics and advance data and standards literacy.

HL7 Europe will continue its productive synergy with CEN/TC251 and formal participation CEN/CENELEC as liaison member. Additionally, thanks to xShare project, we will continue to work closely with IHE-Europe, SNOMED, CDISC, and IEEE towards developing the European Standards and Policy Hub. Beyond the EHDS through funded European projects we will explore issues of One Digital Health, Secondary Use of Data focusing on Genomics of Cardiovascular disease, and Cancer data modeling. At the same time, HL7 Europe seek to actively participate in EHDS fora of the European Commission engaging with umbrella organizations in digital health to advance interoperability.

Acknowledgements

We extend our sincere gratitude to our members, volunteers, partners, and staff for their tireless efforts and unwavering commitment. Your contributions have been pivotal to our success, and we eagerly anticipate our future achievements together.

Key Highlights Summary

Community Growth

- 1,879 new LinkedIn followers (+128% growth)
- 135 active HoF members
- 23 Affiliate countries across Europe

Standards Development

- Published 7+ FHIR IGs for EHDS priority data categories
- Completed 6 ballots
- Advanced Common Cancer Data Model

European Impact

- Active in 12 EU-funded projects
- Participation in key EHDS initiatives
- Supporting 6 countries with Lab IG adoption

Events & Engagement

- 2 successful Working Group Meetings with 100-160 attendees
- 7-webinar series on Lab and FHIR IG adoption
- Global presence at 10+ major conferences

Appendix

Scientific Articles published in 2025

1. Anastasaki, M., Chronaki, C., Moen, A., Kokinou, E., Kokolakis, S., Karagiannidou, M., Mørk, M.-L., & Henni, S. H. (2025). Operationalizing Human Health Indicators to Link with Ecosystem Changes of Water Streams: An OneAquaHealth Protocol. HL7 Europe, University of Oslo, Hellenic Mediterranean University. Created on 2025-05-01. Supported by EU H2020 Project OneAquaHealth GA101086521.
2. Maes C, Cangioli G and Chronaki C (2025) Accelerating European electronic health record exchange format (EEHRxF) implementation across Europe: a policy perspective. *Front. Med.* 12:1648170. doi: 10.3389/fmed.2025.1648170
3. Facile R, Chronaki C, van Reusel P and Kush R (2025) Standards in sync: five principles to achieve semantic interoperability for TRUE research for healthcare. *Front. Digit. Health* 7:1567624. doi: 10.3389/fdgth.2025.1567624
4. Kokolakis, S., Kokinou, E., Karagiannidou, M., & Chronaki, C. (2025). Remote Sensing of Urban Stream Eutrophication and Its Implications for Public Health. In J. Mantas et al. (Eds.), *Global Healthcare Transformation in the Era of Artificial Intelligence and Informatics* (pp. [page numbers not specified]). IOS
5. Kokolakis, Stratos & Kokinou, Eleni & Karagiannidou, Matina & Gerarchakis, Nikos & Vasilakos, Christos & Kotti, Melina & Chronaki, Catherine. (2025). From Space to Stream: Combining Remote Sensing and In Situ Techniques for Comprehensive Stream Health Assessment. *Remote Sensing*. 17. 1532. 10.3390/rs17091532.
6. Kokinou E, Kokolakis S, Karagiannidou M, Anastasaki M, Chronaki C. OA24555. Remote and in situ environmental surveillance of urban streams to support public health issues. *Eur J Public Health*. 2025 Nov 14;35(Suppl 5):ckaf165.040. doi: 10.1093/eurpub/ckaf165.040. PMID: PMC12617155.
7. Neumann, A., Filbert, A.-L., Walz, D., Knörr, L., Csipak, A., Lilienthal, T., Richter, F., Gebauer, J., Langer, T., Ingenerf, J., Schladetzky, J., Saraceno, D., Cangioli, G., Haupt, R., Grabow, D., & Kock-Schoppenhauer, A.-K. (2025). PanCareSurPass Project in Germany: Local Developments for the Multi-Country Implementation Study of SurPass v2.0 at a Single Center in Germany. In E. Andrikopoulou et al. (Eds.), *Intelligent Health Systems – From Technology to Data and Knowledge (Studies in Health Technology and Informatics, Vol. 327, pp. [page numbers])*. IOS Press. <https://doi.org/10.3233/SHTI250506>
8. Markatou, E. A., Knowles, P., Carvalho, L. A., & Chronaki, C. (2025). Expressing Diversity of Health Datasets in the European Health Data Space. *Studies in health technology and informatics*, 329, 1782–1783. <https://doi.org/10.3233/SHTI251212>